CoChat
Sign Up
Cited by 294

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Triptolide and Its Derivatives as Cancer Therapies

Noel, Pawan, Von Hoff, Daniel D., Saluja, Ashok K., Velagapudi, Mohana, Borazanci, Erkut, Han, Haiyong·2019·Trends in Pharmacological Sciences
DOI 10.1016/j.tips.2019.03.002
Open this paper in CoChat — free account

Abstract

Triptolide, a compound isolated from a Chinese medicinal herb, possesses potent antitumor, immunosuppressive, and anti-inflammatory properties, but is clinically limited due to its poor solubility, bioavailability, and toxicity. Recently, Minnelide, a water-soluble prodrug of triptolide, was shown to have potent antitumor activity in various preclinical cancer models. Minnelide is currently in Phase II clinical trials for treatment of advanced pancreatic cancer, which has fueled increased interest in this promising agent. Here, we review the recent advances in the biological activity of triptolide and its analogs, their mechanisms of actions, and their clinical developments. A special emphasis is given to proteins and pathways within the tumor and stromal compartments that are targeted by triptolide and its analogs as well as the ongoing clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.tips.2019.03.002

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 99

  1. Kupchan, 1972, Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii, J. Am. Chem. Soc., 94, 7194, 10.1021/ja00775a078 · DOI
  2. Li, 2014, Triptolide: Progress on research in pharmacodynamics and toxicology, J. Ethnopharmacol., 155, 67, 10.1016/j.jep.2014.06.006 · DOI · Paper page
  3. Ziaei, 2016, Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: a mini review, Avicenna J. Phytomedicine, 6, 149
  4. Zhang, 2017, Overview of medicinally important diterpenoids derived from plastids, Mini Rev. Med. Chem., 17, 988, 10.2174/1389557516666160614005244 · DOI · Paper page
  5. Pigneux, 2008, Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells, Exp. Hematol., 36, 1648, 10.1016/j.exphem.2008.08.002 · DOI
  6. Shao, 2014, Triptolide induces apoptosis of breast cancer cells via a mechanism associated with the Wnt/β-catenin signaling pathway, Exp. Ther. Med., 8, 505, 10.3892/etm.2014.1729 · DOI
  7. Jiang, 2017, Triptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and in vitro, Tumour Biol., 39, 1, 10.1177/1010428317697556 · DOI
  8. Rivard, 2014, Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug, Gynecol. Oncol., 135, 318, 10.1016/j.ygyno.2014.08.031 · DOI
  9. Isharwal, 2017, Minnelide inhibits androgen dependent, castration resistant prostate cancer growth by decreasing expression of androgen receptor full length and splice variants, Prostate, 77, 584, 10.1002/pros.23298 · DOI
  10. Krosch, 2013, Triptolide-mediated cell death in neuroblastoma occurs by both apoptosis and autophagy pathways and results in inhibition of nuclear factor-kappa B activity, Am. J. Surg., 205, 387, 10.1016/j.amjsurg.2013.01.008 · DOI
  11. Oliveira, 2015, Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F, Lab. Invest., 95, 648, 10.1038/labinvest.2015.46 · DOI
  12. Wang, 2016, Triptolide inhibits invasion and tumorigenesis of hepatocellular carcinoma MHCC-97H cells through NF-κB Signaling, Med. Sci. Monit., 22, 1827, 10.12659/MSM.898801 · DOI
  13. Arora, 2017, Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer, PLoS One, 12, 10.1371/journal.pone.0171827 · DOI
  14. Banerjee, 2013, Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1, J. Biol. Chem., 288, 33927, 10.1074/jbc.M113.500983 · DOI
  15. Kupchan, 1974, Selective alkylation: a biomimetic reaction of the antileukemic triptolides?, Science, 185, 791, 10.1126/science.185.4153.791 · DOI
  16. Li, 2009, Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents, J. Med. Chem., 52, 5115, 10.1021/jm900342g · DOI
  17. Aoyagi, 2006, Semisynthesis of C-ring modified triptolide analogues and their cytotoxic activities, Bioorg. Med. Chem. Lett., 16, 1947, 10.1016/j.bmcl.2005.12.098 · DOI
  18. Tang, 2012, Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5-hydroxytriptolide (LLDT-8), Acta Pharmacol. Sin., 33, 1112, 10.1038/aps.2012.108 · DOI
  19. Fu, 2006, (5R)-5-Hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation, J. Neuroimmunol., 175, 142, 10.1016/j.jneuroim.2006.03.011 · DOI
  20. Chen, 2016, LLDT-8 protects against cerebral ischemia/reperfusion injury by suppressing post-stroke inflammation, J. Pharmacol. Sci., 131, 131, 10.1016/j.jphs.2016.05.003 · DOI
  21. Ren, 2007, (5R)-5-hydroxytriptolide (LLDT-8) protects against bleomycin-induced lung fibrosis in mice, Acta Pharmacol. Sin., 28, 518, 10.1111/j.1745-7254.2007.00524.x · DOI
  22. Li, 2014, NF-κB signaling inhibition and anticancer activities of LLDT-246 on human colorectal cancer HCT-116 cells in vitro, Biomed. Pharmacother., 68, 527, 10.1016/j.biopha.2014.05.002 · DOI
  23. Xu, 2017, LLDT-288, a novel triptolide analogue exhibits potent antitumor activity in vitro and in vivo, Biomed. Pharmacother., 93, 1004, 10.1016/j.biopha.2017.06.041 · DOI
  24. Wu, 2012, LLDT-67 attenuates MPTP-induced neurotoxicity in mice by up-regulating NGF expression, Acta Pharmacol. Sin., 33, 1187, 10.1038/aps.2012.88 · DOI
  25. Fidler, 2014, Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102, Cancer Chemother. Pharmacol., 73, 961, 10.1007/s00280-014-2428-6 · DOI
  26. Carter, 2012, MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML, Leukemia, 26, 443, 10.1038/leu.2011.246 · DOI
  27. Reno, 2016, The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer, BMC Cancer, 16, 439, 10.1186/s12885-016-2487-7 · DOI
  28. Fidler, 2003, PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy, Mol. Cancer Ther., 2, 855
  29. Xu, 2014, Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide, Eur. J. Med. Chem., 73, 46, 10.1016/j.ejmech.2013.11.044 · DOI
  30. Aoyagi, 2008, Fluorination of triptolide and its analogues and their cytotoxicity, Bioorg. Med. Chem. Lett., 18, 2459, 10.1016/j.bmcl.2008.02.039 · DOI
  31. Xu, 2014, Semisynthesis of triptolide analogues: effect of B-ring substituents on cytotoxic activities, Bioorg. Med. Chem. Lett., 24, 5671, 10.1016/j.bmcl.2014.10.069 · DOI
  32. Xu, 2014, Design, synthesis and structure-activity relationships studies on the D ring of the natural product triptolide, ChemMedChem, 9, 290, 10.1002/cmdc.201300409 · DOI
  33. Zhou, 2011, Total synthesis of novel D-ring-modified triptolide analogues: structure-cytotoxic activity relationship studies on the D-ring of triptolide, Org. Biomol. Chem., 9, 3176, 10.1039/c0ob01239d · DOI
  34. Chugh, 2012, A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer, Sci. Transl. Med., 4, 10.1126/scitranslmed.3004334 · DOI
  35. Banerjee, 2016, Impaired synthesis of stromal components in response to Minnelide improves vascular function, drug delivery, and survival in pancreatic cancer, Clin. Cancer Res., 22, 415, 10.1158/1078-0432.CCR-15-1155 · DOI
  36. Giri, 2017, Heat shock protein 70 in pancreatic diseases: friend or foe, J. Surg. Oncol., 116, 114, 10.1002/jso.24653 · DOI
  37. Phillips, 2007, Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70, Cancer Res., 67, 9407, 10.1158/0008-5472.CAN-07-1077 · DOI
  38. Zhou, 2007, Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines, Biochim. Biophys. Acta, 1770, 1021, 10.1016/j.bbagen.2007.03.002 · DOI
  39. Soundararajan, 2009, Triptolide: an inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells, Cancer Biol. Ther., 8, 2054, 10.4161/cbt.8.21.9803 · DOI
  40. Yinjun, 2005, Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells, Leuk. Res., 29, 99, 10.1016/j.leukres.2004.05.014 · DOI
  41. Qiao, 2016, Synergistic antitumor activity of gemcitabine combined with triptolide in pancreatic cancer cells, Oncol. Lett., 11, 3527, 10.3892/ol.2016.4379 · DOI
  42. Carter, 2006, Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells, Blood, 108, 630, 10.1182/blood-2005-09-3898 · DOI
  43. Liu, 2013, Triptolide induces apoptosis in human leukemia cells through caspase-3-mediated ROCK1 activation and MLC phosphorylation, Cell Death Dis., 4, e941, 10.1038/cddis.2013.469 · DOI
  44. Li, 2015, Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway, Acta Pharmacol. Sin., 36, 10.1038/aps.2014.162 · DOI
  45. Owa, 2013, Triptolide induces lysosomal-mediated programmed cell death in MCF-7 breast cancer cells, Int. J. Womens Health, 5, 557
  46. Xiong, 2016, Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer, Oncotarget, 7, 23933, 10.18632/oncotarget.8207 · DOI
  47. Kim, 2010, Triptolide inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway, Int. J. Oncol., 37, 1177, 10.3892/ijo_00000769 · DOI
  48. Shi, 2009, Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation, Clin. Cancer Res., 15, 1686, 10.1158/1078-0432.CCR-08-2141 · DOI
  49. Chueh, 2013, Triptolide induced DNA damage in A375: S2 human malignant melanoma cells is mediated via reduction of DNA repair genes, Oncol. Rep., 29, 613, 10.3892/or.2012.2170 · DOI
  50. Borja-Cacho, 2010, TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cells, J. Gastrointest. Surg., 14, 252, 10.1007/s11605-009-1065-6 · DOI
  51. Lee, 2002, Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation, Exp. Mol. Med., 34, 462, 10.1038/emm.2002.64 · DOI
  52. Xiaowen, 2012, Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation, Mol. Biol. Rep., 39, 8763, 10.1007/s11033-012-1737-2 · DOI
  53. Brincks, 2015, Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma, FEBS J., 282, 4747, 10.1111/febs.13532 · DOI
  54. Rousalova, 2013, Minnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo, PLoS One, 8, 10.1371/journal.pone.0077411 · DOI
  55. Chan, 2017, Triptolide induced cell death through apoptosis and autophagy in murine leukemia WEHI-3 cells in vitro and promoting immune responses in WEHI-3 generated leukemia mice in vivo, Environ. Toxicol., 32, 550, 10.1002/tox.22259 · DOI
  56. Yang, 2015, Autophagy upregulation and apoptosis downregulation in DAHP and triptolide treated cerebral ischemia, Mediators Inflamm., 2015, 10.1155/2015/120198 · DOI
  57. Nakazato, 2014, Triptolide induces apoptotic cell death of multiple myeloma cells via transcriptional repression of Mcl-1, Int. J. Oncol., 44, 1131, 10.3892/ijo.2014.2280 · DOI
  58. Liu, 2014, Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation, Int. J. Cancer, 134, 2489, 10.1002/ijc.28583 · DOI
  59. Cheng, 2011, Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions, PLoS One, 6, 10.1371/journal.pone.0023752 · DOI
  60. Ding, 2015, Triptolide suppresses proliferation, hypoxia-inducible factor-1α and c-Myc expression in pancreatic cancer cells, Mol. Med. Rep, 12, 4508, 10.3892/mmr.2015.3960 · DOI
  61. Nomura, 2016, Inhibition of NF-kappa B pathway leads to deregulation of epithelial-mesenchymal transition and neural invasion in pancreatic cancer, Lab. Invest., 96, 1268, 10.1038/labinvest.2016.109 · DOI
  62. Sarkar, 2015, GD3 synthase regulates epithelial–mesenchymal transition and metastasis in breast cancer, Oncogene, 34, 2958, 10.1038/onc.2014.245 · DOI
  63. Zhou, 2015, Inhibition of β-catenin protein expression by triptolide affects self-renewal of liver cancer stem cells, Bangladesh J. Pharmacol., 10, 455, 10.3329/bjp.v10i2.23016 · DOI
  64. Zhao, 2012, Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin, Exp. Mol. Med., 44, 633, 10.3858/emm.2012.44.11.072 · DOI
  65. Vispé, 2009, Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA, Mol. Cancer Ther., 8, 2780, 10.1158/1535-7163.MCT-09-0549 · DOI
  66. Wang, 2011, Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II), PLoS One, 6
  67. Manzo, 2012, Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II, Cancer Res., 72, 5363, 10.1158/0008-5472.CAN-12-1006 · DOI
  68. Titov, 2011, XPB, a subunit of TFIIH, is a target of the natural product triptolide, Nat. Chem. Biol., 7, 182, 10.1038/nchembio.522 · DOI
  69. He, 2015, Covalent modification of a cysteine residue in the XPB subunit of the general transcription factor TFIIH through single epoxide cleavage of the transcription inhibitor triptolide, Angew. Chem. Int. Ed., 54, 1859, 10.1002/anie.201408817 · DOI
  70. Chen, 2015, Stably paused genes revealed through inhibition of transcription initiation by the TFIIH inhibitor triptolide, Genes Dev., 29, 39, 10.1101/gad.246173.114 · DOI
  71. Zhao, 2010, Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro, Toxicology, 267, 70, 10.1016/j.tox.2009.10.023 · DOI
  72. Noel, 2017, Abstract 2978: Discrete super-enhancer networks in pancreatic cancer cells and cancer associated fibroblasts are targeted and modulated by triptolide, Cancer Res., 77, 2978, 10.1158/1538-7445.AM2017-2978 · DOI
  73. Atapattu, 2016, An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth, J. Exp. Med., 213, 1741, 10.1084/jem.20151095 · DOI
  74. Song, 2015, Human dCTP pyrophosphatase 1 promotes breast cancer cell growth and stemness through the modulation on 5-methyl-dCTP metabolism and global hypomethylation, Oncogenesis, 4, e159, 10.1038/oncsis.2015.10 · DOI
  75. Liu, 2015, Computational prediction and experimental validation of low-affinity target of triptolide and its analogues, RSC Adv., 5, 34572, 10.1039/C4RA17009A · DOI
  76. Lu, 2014, TAB1: a target of triptolide in macrophages, Chem. Biol., 21, 246, 10.1016/j.chembiol.2013.12.009 · DOI
  77. Banerjee, 2014, CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide, Clin. Cancer Res., 20, 2388, 10.1158/1078-0432.CCR-13-2947 · DOI
  78. Nomura, 2015, Minnelide effectively eliminates CD133+ side population in pancreatic cancer, Mol. Cancer, 14, 200, 10.1186/s12943-015-0470-6 · DOI
  79. Subramaniam, 2018, Targeting cancer stem cells for chemoprevention of pancreatic cancer, Curr. Med. Chem., 25, 2585, 10.2174/0929867324666170127095832 · DOI
  80. Li, 2014, Triptolide-induced in vitro and in vivo cytotoxicity in human breast cancer stem cells and primary breast cancer cells, Oncol. Rep., 31, 2181, 10.3892/or.2014.3115 · DOI
  81. Liu, 2013, Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors, Cell Death Dis., 4, e948, 10.1038/cddis.2013.467 · DOI
  82. Modi, 2017, Cancer-stromal cross talk augments pancreatic cancer growth that is effectively inhibited by triptolide, J. Am. Coll. Surg., 223, e44, 10.1016/j.jamcollsurg.2016.08.543 · DOI
  83. Zhu, 2010, Triptolide inhibits extracellular matrix protein synthesis by suppressing the Smad2 but not the MAPK pathway in TGFβ1-stimulated NRK-49F cells, Nephrol. Dial. Transplant., 25, 3180, 10.1093/ndt/gfq239 · DOI
  84. Han, 2018, Triptolide prevents extracellular matrix accumulation in experimental diabetic kidney disease by targeting microRNA-137/Notch1 pathway, J. Cell. Physiol., 233, 2225, 10.1002/jcp.26092 · DOI
  85. Yang, 1998, Triptolide induces apoptotic death of T lymphocyte, Immunopharmacology, 40, 139, 10.1016/S0162-3109(98)00036-8 · DOI
  86. Chen, 2005, Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking, Blood, 106, 2409, 10.1182/blood-2005-03-0854 · DOI
  87. Liu, 2006, Immunosuppressant triptolide inhibits dendritic cell-mediated chemoattraction of neutrophils and T cells through inhibiting Stat3 phosphorylation and NF-κB activation, Biochem. Biophys. Res. Commun., 345, 1122, 10.1016/j.bbrc.2006.05.024 · DOI
  88. Matta, 2009, Triptolide induces anti-inflammatory cellular responses, Am. J. Transl. Res., 1, 267
  89. Lin, 2001, Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial, Arthritis Rheum., 44, 2193, 10.1002/1529-0131(200109)44:9<2193::AID-ART373>3.0.CO;2-5 · DOI
  90. Liu, 2013, Triptolide downregulates Treg cells and the level of IL-10, TGF-β, and VEGF in melanoma-bearing mice, Planta Med., 79, 1401, 10.1055/s-0033-1350708 · DOI
  91. Liang, 2008, Triptolide inhibits interferon-γ-induced programmed death-1-ligand 1 surface expression in breast cancer cells, Cancer Lett., 270, 337, 10.1016/j.canlet.2008.05.025 · DOI
  92. Greeno, 2015, Abstract CT207: Phase I dose escalation and pharmokinetic study of 14-O-phosphonooxymethyltriptolide, Cancer Res., 75, CT207, 10.1158/1538-7445.AM2015-CT207 · DOI
  93. Kitzen, 2009, Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours, Eur. J. Cancer, 45, 1764, 10.1016/j.ejca.2009.01.026 · DOI · Paper page
  94. Wang, 2016, Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine, Oncotarget, 7, 8360, 10.18632/oncotarget.7073 · DOI · Paper page
  95. Wu, 2017, Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment, Int. J. Nanomed., 12, 1853, 10.2147/IJN.S131235 · DOI
  96. Zhou, 2015, Autophagy plays an important role in triptolide-induced apoptosis in cardiomyocytes, Toxicol. Lett., 236, 168, 10.1016/j.toxlet.2015.05.013 · DOI
  97. Galvez, 2015, Effects of triptolide on the expression of inflammatory markers in lipopolysaccharide-treated human endothelial cells (HUVEC), FASEB J., 29, 10.1096/fasebj.29.1_supplement.789.1 · DOI
  98. Corson, 2011, Triptolide directly inhibits dCTP pyrophosphatase, ChemBioChem, 12, 1767, 10.1002/cbic.201100007 · DOI
  99. Leuenroth, 2007, Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease, Proc. Natl. Acad. Sci., 104, 4389, 10.1073/pnas.0700499104 · DOI

Cited by

Sorted by citations

See all 294

Metadata

Authors
Noel, P., Von Hoff, D. D., Saluja, A. K., Velagapudi, M., Borazanci, E., & Han, H.
Venue
Trends in Pharmacological Sciences
Publisher
Elsevier BV
Published
2019-05
Volume
40
Issue
5
Pages
327-341
ISSN
0165-6147
DOI
10.1016/j.tips.2019.03.002
Cited by
294
References
4
Language
en
Licence
Funders
  • Lustgarten Foundation (SU2C-AACR-DT-20-16)
  • Seena Magowitz Foundation
  • National Foundation for Cancer Research
  • American Association for Cancer Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Triptolide and Its Derivatives as Cancer Therapies. https://app.cochat.ai/papers/10.1016/j.tips.2019.03.002
The paper
Noel, P., Von Hoff, D. D., Saluja, A. K., Velagapudi, M., Borazanci, E., & Han, H. (2019). Triptolide and Its Derivatives as Cancer Therapies. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2019.03.002